---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-113291"
form_type: "8-K"
ticker: "VRDN"
cik: "0001590750"
company_name: "Viridian Therapeutics, Inc.\\DE"
filed_at: "2025-05-06T23:59:59+00:00"
generated_at: "2026-05-22T11:51:21.777919+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Viridian Q1 cash $636.6M; veligrotug BLA on track for H2 2025

## Summary
- Cash, cash equivalents, and short-term investments $636.6M at March 31, 2025, down from $717.6M in December 2024; runway into H2 2027.
- R&D expenses $76.8M in Q1 2025 vs $40.9M in Q1 2024, driven by more clinical trials and increased headcount.
- Veligrotug BLA submission to FDA on track for H2 2025; EMA MAA expected in H1 2026.
- Phase 3 topline data for VRDN-003 (subcutaneous TED) expected H1 2026 from REVEAL-1 and REVEAL-2 trials.
- VRDN-006 phase 1 healthy volunteer data expected Q3 2025; VRDN-008 IND submission targeted for year-end 2025.

## SEC filing metadata
- accession: 0001193125-25-113291
- form_type: 8-K
- ticker: VRDN
- cik: 0001590750
- company_name: Viridian Therapeutics, Inc.\DE
- filed_at: 2025-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590750/000119312525113291/0001193125-25-113291-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590750/000119312525113291/d937417d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-113291
- JSON: https://secwatch.observer/filing/0001193125-25-113291.json
- Plain text: https://secwatch.observer/filing/0001193125-25-113291.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.